216394-06-8

Usage

Uses

Used in Pharmaceutical Industry:
(1R,2R)-(-)-2-Benzyloxycyclohexylamine is used as an intermediate in the synthesis of various pharmaceutical compounds due to its unique chiral structure. Its specific geometric arrangement allows for the creation of enantiomerically pure drugs, which is crucial for ensuring the desired therapeutic effects and minimizing potential side effects.
Used in Research Applications:
In the field of research, (1R,2R)-(-)-2-Benzyloxycyclohexylamine serves as a valuable compound for studying the effects of chirality on drug interactions, metabolism, and efficacy. Its use in research helps to advance the understanding of stereochemistry and its implications in drug design and development.
Used in Drug Delivery Systems:
(1R,2R)-(-)-2-Benzyloxycyclohexylamine can be incorporated into drug delivery systems to improve the bioavailability and therapeutic outcomes of pharmaceuticals. Its unique structure may allow for the development of novel drug carriers, enhancing the delivery of active ingredients to target sites within the body.

InChI:InChI=1/C13H19NO/c14-12-8-4-5-9-13(12)15-10-11-6-2-1-3-7-11/h1-3,6-7,12-13H,4-5,8-10,14H2/t12-,13-/m1/s1

Upstream product

• 18421-15-3 (+/-)-N-(cis-2-hydroxy-cyclohexyl)-acetamide 
• 18421-15-3 (±)-N-((1R,2R)-2-hydroxycyclohexyl)acetamide 
• 100-44-7 benzyl chloride 
• 98454-36-5 N-((1R,2R)-2-Benzyloxy-cyclohexyl)-acetamide 
• 98454-36-5 N-((1R,2S)-2-Benzyloxy-cyclohexyl)-acetamide 
• 85761-38-2 (+/-)-trans-2-benzyloxycyclohexan-1-ol 

Downstream Products

• 40571-86-6 rac-(1R,2R)-2-(benzylamino)cyclohexanol 
• 141478-34-4 1-(N-benzylamino)-2-cyclohexanone 
• 121282-70-0 (+/-)-trans-1-hydroxy-2-tert-butoxycarbonylamino-cyclohexane 
• 745783-98-6 C₁₄H₁₇NOS 
• 1574347-88-8 N-[(1R,2R)-2-(benzyloxy)cyclohexyl]octadecane-1-sulphonamide 
• 1574347-89-9 N-[(1R,2R)-2-hydroxycyclohexyl]octadecane-1-sulphonamide 

Relevant academic research and scientific papers

Hybrid Organo- and Biocatalytic Process for the Asymmetric Transformation of Alcohols into Amines in Aqueous Medium

A hybrid organo- and biocatalytic system for the asymmetric conversion of racemic alcohols into amines was developed. Combining an organocatalyst, AZADO, an oxidant, NaOCl, and an enzyme, ω-transaminase, we implemented a one-pot oxidation-transamination sequential process in aqueous medium. The method showed broad substrate scope and was successfully applied to conventional secondary alcohols and sterically hindered β-substituted cycloalkanols, where a highly stereoselective dynamic asymmetric bioamination enabled us to set up both contiguous stereocenters with very high enantio- and diastereomeric ratio (>90% yield, >99% ee, and up to 49:1 dr).

Broadening the chemical scope of laccases: Selective deprotection of N-benzyl groups

Laccase from Trametes versicolor together with TEMPO has been found to be a very efficient system to deprotect N-benzylated primary amines, differing from previously described methods since it uses oxygen as a mild oxidant in aqueous medium. Chemoselective removal of the benzyl group was achieved with excellent yields when secondary amines and alcohol moieties were also present.

Method for Producing O-Alkylated Aminoalcohols

A process for preparing O-alkylated amino alcohols by reacting N-unsubstituted or N-monosubstituted amino alkoxide salts with alkyl halides, the amino alkoxide salts being formed by means of alkali metal or alkaline earth metal hydroxides.

Method For Producing O-Alkylated Cyclic Aminoalcohols

A process for preparing O-alkylated amino alcohols of the formula (I) by reacting N-unsubstituted or N-monosubstituted amino alkoxide salts with alkyl halides, the amino alkoxide salts being formed by means of alkoxides

IL-8 RECEPTOR ANTAGONISTS

This invention relates to the use of phenyl ureas of formulas (I) and (II) in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). The variables of (I) and (II) are defined herein. STR1